YVYulia Vugmeyster

Yulia Vugmeyster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yulia Vugmeyster has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Kathy Howell

    3 shared publications
  • A. Bakshi

    Bioanalytical Research and Development, Genentech Inc., South San Francisco, California

    1 shared publication
  • Anahid Bakshl

    Bioanalytical Research and Development Department, Genentech, Inc., South San Francisco, California

    1 shared publication
  • C. Flores

    Bioanalytical Research and Development, Genentech Inc., South San Francisco, California

    1 shared publication
  • Clarissa Flores

    Bioanalytical Research and Development Department, Genentech, Inc., South San Francisco, California

    1 shared publication
  • Daniel Combs

    Clinical and Experimental Pharmacology Department, Genentech, Inc., South San Francisco, CA, USA

    1 shared publication

Latest Publications

  • Open Access

    B‐cell subsets in blood and lymphoid organs in Macaca fascicularis

    by Y. Vugmeyster, K. Howell, A. Bakshi, C. Flores, O. Hwang, K. McKeever

    Background: Cynomolgus monkeys (Macaca fascicularis) are widely used animal models in biomedical research. However, the phenotypic characteristics of cynomolgus monkey (CM) B cells in peripheral blood (PB) and lymphoid organs are poorly understood.Methods: FACS analyses of PB‐, spleen‐, lymph node (LN)‐, and bone marrow (BM)‐derived B cells were performed.Results: CM peripheral blood B cells have a smaller fraction of CD27− (naive) cells (∼40%), as compared to human blood samples (∼70%). Similar to humans, an early activation marker, CD23, is expressed more on CD27− CM naive B cells, as compared to CD27+ B cells. The mean fraction of B cells exhibiting a memory phenotype is similar to that seen in human blood. Unlike humans, CM blood contains a subset of CD20++CD80+CD21−IgM+/−CD27+CD19+FSC++BAFF‐Rlow B cells that are likely of germinal center origin. Thus, CM blood contains (i) a higher percentage of B cells that express the co‐stimulatory molecule CD80, and (ii) a lower fraction of B cells that are CD21+, as compared to human blood. Due to the relative paucity of information on B‐cell subsets in organs of healthy humans, a direct comparison between human and CM lymphoid organ data is limited. The fraction of CD27+ and CD23+ B cells appears to be similar, while the fraction of CD80+ B cells appears to be higher than that seen in human lymphoid organs. CM spleens and to some extent lymph nodes have a distinct subset of CD21++ cells that are also CD80+/−CD23lowIgM++CD27+/−FSC++. This subset is phenotypically similar to the marginal zone B cells present in human spleen and LN samples. We also provide detailed analyses on the fraction of lymphoid organ B cells that express CD21, CD23, CD32, and/or CD80 B‐cell markers.Conclusions: In general, cynomolgus monkey B‐cell subsets are similar to those seen in humans, as well as to those seen in other nonhuman primates. However, there are some clear differences between human and cynomolgus monkey B‐cell subsets. These findings have direct implications for a variety of in vivo studies in cynomolgus monkeys, ranging from basic research on primate B‐cell differentiation to models of infectious diseases and trials of new B‐cell targeting therapeutic agents.


  • Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys

    by Yulia Vugmeyster, Kathy Howell, Kathleen McKeever, Daniel Combs, Eleanor Canova-Davis


  • Open Access

    Effect of anti‐CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix

    by Yulia Vugmeyster, Kathy Howell, Anahid Bakshl, Clarissa Flores, Eleanor Canova‐Davis

    Background Cynomolgus monkeys are widely used animal models in biomedical research. The differences between cynomolgus monkey and human B cells are not completely understood. However, these differences are of crucial importance for interpretation of data from studies on new therapeutic agents aimed at B-cell depletion, such as anti-CD20 monoclonal antibodies. Methods Multicolor fluorescence-activated cell sorting analysis of peripheral blood B cells was performed on samples treated ex vivo with the anti-CD20 therapeutic monoclonal antibody, Rituxan, in a whole blood matrix. Results In contrast to humans, cynomolgus monkeys had two distinct B-cell subsets, CD20highCD40lowCD21− and CD20lowCD40highCD21+. These B-cell subsets had a 2.5-fold difference in the EC50 for Rituxan binding and differed significantly in their in vitro susceptibility to Rituxan depletion. Human B cells were similar to the CD20lowCD40highCD21+ cynomolgus monkey B cells with regard to their EC50 for Rituxan and response to Rituxan in a whole blood matrix assay. CD21 was upregulated, whereas CD40 was downregulated at incubation with Rituxan in the CD20lowCD40highCD21+ monkey and human B cells in a concentration-dependent manner. Conclusions These findings have direct implications for in vivo studies of therapeutic agents that target B cells in cynomolgus monkeys and for extrapolation of the results to humans. In addition, our data are consistent with the model in which CD20, CD21, and CD40 exist in a supramolecular complex that is affected by anti-CD20 monoclonal antibodies. Cytometry Part A 52A:101–109, 2003.